FBLG · FibroBiologics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 31, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Mar 30, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Mar 30, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FBLG
this stock
FibroBiologics, Inc.
|
$12.98M | — | — | — | 2.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +22.8% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.82B | +10.4% | +20.8% | 20.4 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.5% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +411.4% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Mar 30, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FBLG | +38.3% | +124.7% | — | +13.4% | — |
| SPY | -0.1% | -0.6% | +14.9% | -0.3% | +12.2% |
| vs SPY | +38.4% | +125.3% | — | +13.6% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.